Pixantrone

Summary

Pixantrone (CHEMBL167731) is an approved small molecule (ATC L01DB11); indicated across 8 conditions including neoplasm and lymphoma; with CIViC clinical evidence for 1 variant-indication association (e.g. TOP2A TOP2A/90 in leukemia).

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: L01DB11
• Indications: 8 conditions
• Clinical trials: 8
• Precision-oncology evidence (CIViC): 1 variant–indication association
• Chemistry: 325.4 Da · C17H19N5O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL167731
Name	Pixantrone
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	134019
ATC	L01DB11
Molecular formula	C17H19N5O2
Molecular weight	325.4
InChIKey	PEZPMAYDXJQYRV-UHFFFAOYSA-N

SMILES: C1=CC(=C2C(=C1NCCN)C(=O)C3=C(C2=O)C=NC=C3)NCCN

IUPAC name: 6,9-bis(2-aminoethylamino)benzo[g]isoquinoline-5,10-dione

Also known as: BBR 2778, BBR-2778, BBR2778, Pixantrona, Pixantrone, PIXANTRONE, SID225144373, Pixantrone (dimaleate)

Parent form; salt/anhydrous children: CHEMBL537394, CHEMBL2103844

Patent coverage: 3,544 distinct patent families (14,722 SureChEMBL compound mentions), from 2 matched compound structure(s). One matched structure accounts for 14,460 (98%) of the total. Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

8 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
neoplasm	4	MONDO:0005070	EFO:0000616
lymphoma	3	MONDO:0005062	EFO:0000574
diffuse large B-cell lymphoma	3	MONDO:0018905	EFO:0000403
non-Hodgkin lymphoma	3	MONDO:0018908	EFO:0005952
follicular lymphoma	3	MONDO:0018906	MONDO:0018906
neoplasm of mature B-cells	3	MONDO:0004949	EFO:0000096
B-cell chronic lymphocytic leukemia	1	MONDO:0004948	EFO:0000095
acute myeloid leukemia	1	MONDO:0018874	EFO:0000222

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE3	3
PHASE1	3
PHASE2	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00088530	PHASE3	COMPLETED	BBR 2778 for Relapsed, Aggressive Non-Hodgkin’s Lymphoma (NHL)
NCT00577161	PHASE3	WITHDRAWN	Fludarabine, Pixantrone and Rituximab vs Fludarabine and Rituximab forRelapsed or Refractory Indolent NHL
NCT01321541	PHASE3	COMPLETED	Comparison of Pixantrone + Rituximab With Gemcitabine + Rituximab in Patients With Aggressive B-cell Non-Hodgkin Lymphoma or Follicular Grade 3 Lymphoma Who Have Relapsed After Therapy and Are Not Eligible for Stem Cell Transplant
NCT02499003	PHASE2	COMPLETED	GOAL: GA101 Plus Pixantrone for Relapsed Aggressive Lymphoma
NCT03458260	PHASE2	COMPLETED	Study of Pixantrone in CD20+ Relapsed/Refractory Aggressive Non-Hodgkin Lymphoma
NCT01491841	PHASE1	COMPLETED	IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin’s Lymphoma
NCT01632436	PHASE1	WITHDRAWN	Pharmacokinetic and Safety Study of Pixantrone in Patients With Metastatic Cancer and Hepatic Impairment
NCT02800889	PHASE1	WITHDRAWN	Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer

Clinical evidence (CIViC)

Variant × indication × effect (1 predictive associations from 1 curated evidence items):

Variant	Indication	Effect	Therapy	Level	CIViC
TOP2A TOP2A/90	Leukemia	Resistance	Etoposide + Pixantrone + DVP Regimen + 4’-(9-acridinylamino)methanesulfon-m-anisidide + MVT Regimen	CIViC D	EID9635

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).